Clinical trials: Hematological Neoplasm
Anemia, Bone Marrow Failure
European Rare Blood Disorders Platform (ENROL)
ENROL, the European Rare Blood Disorders Platform has been conceived in the core of ERN-EuroBloodNet as an umbrella for both new and already existing registries on Rare Hematological Diseases (RHDs).
- Conditions
- Anemia, Bone Marrow Failure, Bleeding Disorder, Iron Metabolism Disorders
- Trial name
- ENROL (NCT06250595)
- Testing
- Collection of clinical and laboratory data from EHR.
- Where
- Spain
- Volunteers
- 37,090 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma of Soft Tissue
A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies
A Study of Murine CD19 CAR-T Cells Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies.
- Trial name
- NCT04532281
- Testing
- Murine CD19 CAR-T cells
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang University
Hematologic Malignancy
Besponsa Post Marketing Surveillance Study
Besponsa is approved for the treatment of R/R B-cell ALL in Korea. In accordance with the Standards for Re-examination of New Drug, it is required to conduct a PMS.
- Trial name
- NCT04307134
- Testing
- Inotuzumab ozogamicin
- Where
- South Korea
- Volunteers
- 108 people
- Sponsor
- Pfizer
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Survey Assessment of Patient and Provider Impressions of Telemedicine in Radiation Oncology
To understand more about the opinions of patients and health providers on the use of telemedicine in radiation oncology.
- Trial name
- NCT05496972
- Testing
- Survey Administration
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Pediatric Patients, Hematologic Malignancy
TCR Alpha/Beta and CD19-deplete Haplo-HSCT
This is an open label, interventional, non-randomized, phase II trial of TCR alpha/beta and CD19-depeleted allogeneic HCT in pediatric patients with hematologic disease.
- Conditions
- Pediatric Patients, Hematologic Malignancy, Other Hematologic Condition
- Trial name
- NCT05288595
- Testing
- CliniMACS Plus Instrument
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Multiple Myeloma
A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)
This is a non-randomized, open label, phase I/II, dose-escalation study, involving a single injection of Temferon, an investigational advanced therapy consisting of autologous CD34+-enriched hematopoietic stem and progenitor…
- Trial name
- NCT03875495
- Testing
- Temferon
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- Genenta Science
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)
This is an open-label, non-randomised, multi-centre phase I-II study of CHR-2797 administered orally once a day. The study involves two distinct phases: Phase I: an open-label, dose-escalating phase of the study to explore the…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
- Trial name
- NCT00689000
- Testing
- CHR-2797 (tosedostat): Aminopeptidase inhibitor
- Where
- United Kingdom
- Volunteers
- 57 people
- Sponsor
- Chroma Therapeutics
Lymphoma, B-Cell, Small Lymphocytic Lymphoma
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed or refractory hematologic malignancies.
- Conditions
- Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
- Trial name
- NCT03162536
- Testing
- Nemtabrutinib
- Where
- 10 sites in United States
- Volunteers
- 190 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Adult Hodgkin Lymphoma, Adult Myelodysplastic Syndrome
Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT
This pilot phase I/II trial studies the side effects and how well sirolimus and mycophenolate mofetil work in preventing graft versus host disease (GvHD) in patients with hematologic malignancies undergoing hematopoietic stem…
- Conditions
- Adult Hodgkin Lymphoma, Adult Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT02728700
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Stanford University
Polycythemia Vera (PV)
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
This is a Phase 3 open-label, multicenter, single arm study designed to evaluate the efficacy and safety and tolerability of P1101 patient with PV or ET in long-term.
- Trial name
- NCT04655092
- Testing
- P1101 (Ropeginterferon alfa-2b)
- Where
- 6 sites in Japan
- Volunteers
- 67 people
- Sponsor
- PharmaEssentia Japan K.K.
Hematological Malignancies
Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant
This observational study is proposed to observe the effect of high-dose, post-transplantation cyclophosphamide after a T cell-replete, HLA-matched PBSC graft from an HLA-identical or mismatched donor.
- Trial name
- NCT02300571
- Where
- 2 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Polycythemia Vera, Essential Thrombocythemia
Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients
The purpose of the study is to isolate and characterize stem cells of patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) to find out why these cells are not working the way they should be and why they seem to…
- Trial name
- NCT01970930
- Testing
- Blood specimen
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Pain Management, Anxiety
Distraction With Virtual Reality From Pain and Anxiety for Patients With Hematological Malignancies
The goal of this clinical trial] is to study the effectiveness of Virtual Reality (VR) in reducing pain and anxiety during painful procedures for patients with hematological malignancies The main question[s] it aims to answer…
- Conditions
- Pain Management, Anxiety, Procedures, Hematological Neoplasms
- Trial name
- NCT07085065
- Testing
- VR session
- Where
- Tunisia
- Volunteers
- 365 people
- Sponsor
- Yesmine Amara
Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the cancer or cells in blood.
- Conditions
- Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes, Hematological Malignancies, B-cell Malignancy, Low-grade
- Trial name
- NCT02269592
- Where
- 7 sites in United States
- Volunteers
- 10,000 people
- Sponsor
- Dana-Farber Cancer Institute
Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors, Hematologic Disease
Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors
This clinical trial aims to evaluate the efficacy and safety of CAR-T cell therapy in patients with relapsed/refractory hematologic malignancies.
- Trial name
- NCT06849921
- Testing
- Cellular Therapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Ruijin Hospital
Polycythemia Vera
Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera
The purpose of this study is the identification of the maximum tolerated dose (MTD) of the investigational medicinal product. Moreover the safety and tolerability will be assessed and an exploratory analysis of efficacy and…
- Trial name
- PEGINVERA (NCT01193699)
- Testing
- PEG-P-INF alpha-2b (P1101)
- Where
- 6 sites in Austria
- Volunteers
- 24 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients
Allogeneic transplant can sometimes be an effective treatment for leukemia. In a traditional allogeneic transplant, patients receive very high doses of chemotherapy and/or radiation therapy, followed by an infusion of their…
- Trial name
- NCT02433483
- Testing
- Cytarabine, Intrathecal Triples, HPC-A
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- St. Jude Children's Research Hospital
AL Amyloidosis
Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis
This study aims to evaluate the use of teclistamab in systemic AL amyloidosis and answer whether teclistamab can improve the rate of complete hematological response. This is a single-arm, multi-center, prospective study.
- Trial name
- NCT06699394
- Testing
- Teclistamab (Tec)
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Peking University People's Hospital
Hematopoietic and Lymphatic System Neoplasm
Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial
This phase II trial studies how well adding axatilimab to standard of care (SOC) therapy works in preventing graft versus host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (HCT) in patients with…
- Trial name
- NCT07349771
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Axatilimab, Biospecimen Collection
- Where
- 3 sites in United States
- Sponsor
- Mayo Clinic
Hematologic Malignancy, Leukemia, Acute
Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies
This is a prospective, observational cohort study to assess the frequency with which neutropenic patients with hematologic malignancies and hematopoietic cell transplant (HCT) recipients are colonized with…
- Conditions
- Hematologic Malignancy, Leukemia, Acute, Neutropenia, Bloodstream Infection
- Trial name
- SCENE (NCT04710212)
- Testing
- No intervention.
- Where
- 6 sites in United States
- Volunteers
- 168 people
- Sponsor
- Duke University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.